Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.drudis.2021.05.008 http://scihub22266oqcxt.onion/10.1016/j.drudis.2021.05.008 34023496!8139175!34023496     free     free     free       Drug+Discov+Today 2021 ; 26 (10): 2367-2376 Nephropedia Template TP {{tp|p=34023496|t=2021. Drug combination therapy for emerging viral diseases |pdf=|usr=}}{{34023496}} gab.com Text Drug combination therapy for emerging viral diseases JO: Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=34023496 #FOAvip Effective therapeutics to combat emerging viral infections are an unmet need. Historically, treatments for chronic viral infections with single drugs have not been successful, as exemplified by human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Combination therapy for these diseases has led to improved clinical outcomes with dramatic reductions in viral load, morbidity, and mortality. Drug combinations can enhance therapeutic efficacy through additive, and ideally synergistic, effects for emerging and re-emerging viruses, such as influenza, severe acute respiratory syndrome-coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS)-CoV, Ebola, Zika, and SARS-coronavirus 2 (CoV-2). Although novel drug development through traditional pipelines remains a priority, in the interim, effective synergistic drug candidates could be rapidly identified by drug-repurposing screens, facilitating accelerated paths to clinical testing and potential emergency use authorizations. Twit Text FOAVip Drug combination therapy for emerging viral diseases ????Drug Discov Today http://www.kidney.de/pget.php?&tw=1&pmid=34023496 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34023496 #FOAvip English Wikipedia <ref>{{Cite pmid|34023496}}</ref> Drug combination therapy for emerging viral diseases #MMPMID34023496 Shyr ZA; Cheng YS; Lo DC; Zheng W Drug Discov Today 2021[Oct]; 26 (10): 2367-2376 PMID34023496show ga Effective therapeutics to combat emerging viral infections are an unmet need. Historically, treatments for chronic viral infections with single drugs have not been successful, as exemplified by human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. Combination therapy for these diseases has led to improved clinical outcomes with dramatic reductions in viral load, morbidity, and mortality. Drug combinations can enhance therapeutic efficacy through additive, and ideally synergistic, effects for emerging and re-emerging viruses, such as influenza, severe acute respiratory syndrome-coronavirus (SARS-CoV), Middle East respiratory syndrome (MERS)-CoV, Ebola, Zika, and SARS-coronavirus 2 (CoV-2). Although novel drug development through traditional pipelines remains a priority, in the interim, effective synergistic drug candidates could be rapidly identified by drug-repurposing screens, facilitating accelerated paths to clinical testing and potential emergency use authorizations. |*Drug Combinations[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |Communicable Diseases, Emerging/*drug therapy[MESH] |Drug Repositioning[MESH] |Drug Therapy, Combination/*trends[MESH] |Humans[MESH]Drug combination therapy for emerging viral diseases (epmc).pdf DeepDyve Pubget Overpricing